Literature DB >> 12531158

Chronic hypnotic use: deadly risks, doubtful benefit. REVIEW ARTICLE.

Daniel F. Kripke1.   

Abstract

In the United States, roughly 2/3 of all hypnotic prescriptions go to chronic users, who have taken hypnotics for an average of 5 years or more. Two large prospective epidemiological studies have shown that reported hypnotic use, especially use 30 times per month, is associated with an excess hazard of death. Indeed, use of hypnotics 30 times per month is associated with a similar mortality hazard to smoking 1-2 packs of cigarettes per day. Moreover, the hypnotic user's wish to improve daytime function is usually unfulfilled. The preponderance of evidence is that hypnotics impair performance, cognition and memory, increase the risk of automobile accidents and falls and promote unfavourable changes in personality. Due to tolerance, the sleep-promoting effects of hypnotics appear to be lost with chronic use. With long-term use, there is little controlled evidence that hypnotics produce benefits of any sort. More study of long-term hypnotic effects by public agencies is needed, but available evidence weighs strongly against long-term prescribing.

Entities:  

Year:  2000        PMID: 12531158     DOI: 10.1053/smrv.1999.0076

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  35 in total

Review 1.  Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review.

Authors:  Hervé Allain; Danièle Bentué-Ferrer; Elisabeth Polard; Yvette Akwa; Alain Patat
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 2.  Who are the long sleepers? Towards an understanding of the mortality relationship.

Authors:  Michael A Grandner; Sean P A Drummond
Journal:  Sleep Med Rev       Date:  2007-07-10       Impact factor: 11.609

3.  Non-pharmacological management of chronic insomnia in primary care.

Authors:  Brian McKinstry; Philip Wilson; Colin Espie
Journal:  Br J Gen Pract       Date:  2008-02       Impact factor: 5.386

4.  Who should sponsor sleep disorders pharmaceutical trials?

Authors:  Daniel F Kripke
Journal:  J Clin Sleep Med       Date:  2007-12-15       Impact factor: 4.062

5.  Hypnotics and mortality risk.

Authors:  Matt T Bianchi; Robert J Thomas; Jeffrey M Ellenbogen
Journal:  J Clin Sleep Med       Date:  2012-08-15       Impact factor: 4.062

6.  Continuing Versus New Prescriptions for Sedative-Hypnotic Medications: United States, 2005-2012.

Authors:  Christopher N Kaufmann; Adam P Spira; Colin A Depp; Ramin Mojtabai
Journal:  Am J Public Health       Date:  2016-09-15       Impact factor: 9.308

7.  Long-term sedative use among community-dwelling adults: a population-based analysis.

Authors:  Deirdre Weymann; Emilie J Gladstone; Kate Smolina; Steven G Morgan
Journal:  CMAJ Open       Date:  2017-03-03

Review 8.  Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment.

Authors:  M V Vitiello; S Borson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

9.  Use of Sedative-Hypnotics and Mortality: A Population-Based Retrospective Cohort Study.

Authors:  Jae-Won Choi; Joonki Lee; Sun Jae Jung; Aesun Shin; Yu Jin Lee
Journal:  J Clin Sleep Med       Date:  2018-10-15       Impact factor: 4.062

10.  Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs.

Authors:  Børge Sivertsen; Siri Omvik; Ståle Pallesen; Inger Hilde Nordhus; Bjørn Bjorvatn
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.